60P - Establishment and characterization of a novel lung adenocarcinoma cell line HX-JCJ harboring MET ex14 skipping mutation

Background

MET exon14 skipping mutations are considered an important driver of oncogenesis and are observed in approximately 3-4% of patients diagnosed with non-small cell lung cancer (NSCLC). Various MET tyrosine kinase inhibitors (TKIs) are currently being developed for clinical use in the treatment of NSCLC patients with MET exon14 skipping mutation. However, preclinical research in this area has been restricted due to the rarity of MET exon14 mutant cases. Almost all the studies conducted have been on patients or patent-derived xenografts (PDX). To address this issue, there is a need for a NSCLC cell line with MET exon14 skipping mutation. In this study, we have established a novel lung adenocarcinoma cell line that harbors MET exon14 skipping mutation. This new cell line represents a valuable tool for the research of MET targeted therapy.

Methods

The cell line was established using the primary tumor tissue from a 67-year-old male patient with NSCLC, and named as HX-JCJ. The cell line has been growing well for more than 10 months and has been passaged over 50 times. Phenotypes of the cell line, such as proliferation, invasion, protein expression, and xenografting were characterized in vitro and in vivo. MET ex14 skipping mutation of this cell line was validated by RT-PCR and Sanger sequencing.

Results

Drug screen showed that this cell line was extremely sensitive to KC1036 (IC50=4.8nm), which is a home-made small molecule inhibitor with strong anti-MET and anti-angiogensis activity.

Conclusions

In conclusion, we successfully established a novel NSCLC cell line (HX-JCJ) harboring MET ex14 skipping mutation from the primary tumor tissue, which may provide a promising cell model for further MET relevant research.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.